𝗗𝗿. 𝗖𝗵𝘂𝗻 𝗖𝗵𝗶𝗲𝗻 and colleagues at Latigo Biotherapeutics, Inc. used Sophion's QPatch to characterize a new peptide, WRPRFa, revealing its ability to slow ASIC3 desensitisation, enhance proton sensitivity, and uncover tachyphylaxis: https://t.co/UJkPGnb4Uu
Team USA Stat Leaders 🇺🇸📈
Katey Forth, Kelly Hyland and Alex Nord lead the way after two days of action! See the full stat breakdown through the link: https://t.co/lIYeP6hsOS
#PullForUS | #USAUltimate
Robert Redford may have left us, but his smile, his gaze, and the stories he brought to life will always stay with us. A man who lived fully with passion, leaving behind a deep love for art and nature.
#RobertRedford#CinemaLegend#AlwaysRemembered#LegacyLivesOn
Latigo Biotherapeutics, Inc. just stepped into the limelight with a whopping $135 million funding! After flying under the radar, they've just announced their grand entrance with a Series A financing that's turning heads.
The mastermind behind their launch? Westlake Village BioPartners®, who not only incubated Latigo but also led this impressive funding round.
And they weren't alone; 5AM Ventures and Foresite Capital jumped in as co-leads, with Corner Ventures also throwing their hat into the ring.
What's Latigo all about?
They're on a mission we can all get behind – developing non-opioid pain medicines. Yep, they're targeting those pesky pain points without the opioid baggage, focusing on genetically validated targets.
It's the kind of science that could really shake things up, offering relief without the risk of addiction.
Keep your eyes on Latigo Biotherapeutics. With this kind of backing and a mission that hits close to home for many, they're definitely ones to watch in the biotech scene.
#biotech #biotechnology #fundingnews #startupfunding
Thank you to John Gilchrist at Latigo Biotherapeutics, Inc. for providing our latest testimonial.
See what other customers say about working with Metrion: https://t.co/rmy7kI89hh
#DrugDiscovery#IonChannels#CRO